Takeda have entered into an agreement to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of select non-core products in Japan to Teijin Pharma, a Tokyo-based pharmaceutical company, for approximately 1.25 billion (¥133.0 billion).
The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina, Liovel, Inisync and Zafatek) sold in Japan, which generated total sales of approximately $289 million (¥30.8 billion) in 2019. The products included are outside of Takeda’s chosen business areas of gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.
According to Takeda this is just a continued execution of its operational and financial commitments of optimizing its portfolio for growth and paying down long-term debt. Takeda intends to use the proceeds from the sale to reduce its debt and accelerate deleveraging towards its target of 2x net debt/adjusted EBITDA within FY2021 – FY2023.
Takeda's divestiture strategy has allowed it to exceed its $10 billion non-core asset divestiture target. Including this transaction, Takeda has announced 12 deals since January 2019, for a total aggregate value of up to approximately $12.9 billion.
Read the Takeda statement